JPWO2019229193A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019229193A5
JPWO2019229193A5 JP2020566612A JP2020566612A JPWO2019229193A5 JP WO2019229193 A5 JPWO2019229193 A5 JP WO2019229193A5 JP 2020566612 A JP2020566612 A JP 2020566612A JP 2020566612 A JP2020566612 A JP 2020566612A JP WO2019229193 A5 JPWO2019229193 A5 JP WO2019229193A5
Authority
JP
Japan
Prior art keywords
lymphocyte
peptide
poly
interest
dna molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525517A5 (https=
JP2021525517A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/064109 external-priority patent/WO2019229193A1/en
Publication of JP2021525517A publication Critical patent/JP2021525517A/ja
Publication of JP2021525517A5 publication Critical patent/JP2021525517A5/ja
Publication of JPWO2019229193A5 publication Critical patent/JPWO2019229193A5/ja
Priority to JP2024034648A priority Critical patent/JP2024063211A/ja
Pending legal-status Critical Current

Links

JP2020566612A 2018-05-30 2019-05-29 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング Pending JP2021525517A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024034648A JP2024063211A (ja) 2018-05-30 2024-03-07 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2018/064299 2018-05-30
EP2018064299 2018-05-30
PCT/EP2019/064109 WO2019229193A1 (en) 2018-05-30 2019-05-29 Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024034648A Division JP2024063211A (ja) 2018-05-30 2024-03-07 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング

Publications (3)

Publication Number Publication Date
JP2021525517A JP2021525517A (ja) 2021-09-27
JP2021525517A5 JP2021525517A5 (https=) 2022-05-31
JPWO2019229193A5 true JPWO2019229193A5 (https=) 2022-05-31

Family

ID=62620827

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566612A Pending JP2021525517A (ja) 2018-05-30 2019-05-29 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング
JP2024034648A Pending JP2024063211A (ja) 2018-05-30 2024-03-07 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024034648A Pending JP2024063211A (ja) 2018-05-30 2024-03-07 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング

Country Status (12)

Country Link
US (1) US20210254106A1 (https=)
EP (1) EP3802841A1 (https=)
JP (2) JP2021525517A (https=)
KR (1) KR20210016446A (https=)
CN (1) CN112384627A (https=)
AU (1) AU2019276261A1 (https=)
BR (1) BR112020024354A2 (https=)
CA (1) CA3100112A1 (https=)
EA (1) EA202092807A1 (https=)
MX (1) MX2020012895A (https=)
SG (1) SG11202011280SA (https=)
WO (1) WO2019229193A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114181901B (zh) * 2021-12-08 2024-02-02 杭州中赢生物医疗科技有限公司 一种免疫细胞的体外诱导扩增和冻存的方法
EP4522736A2 (en) * 2022-05-10 2025-03-19 Editas Medicine, Inc. Genome editing of b cells
EP4698226A2 (en) * 2023-04-17 2026-02-25 Be Biopharma, Inc. Engineered cell preparations for treatment of hemophilia
CN117063890B (zh) * 2023-07-11 2025-12-05 吉林大学 一种heca基因不表达的异种移植供体猪及制备方法
WO2025147573A2 (en) * 2024-01-05 2025-07-10 Immusoft Corporation Glp-1 expressing modified b cells for the treatment of metabolic disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
ATE271122T1 (de) 1996-11-12 2004-07-15 Pfizer Attenuierter lebender neospora impfstoff
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
AU2002953381A0 (en) * 2002-12-18 2003-01-09 Diatech Pty Ltd In vivo affinity maturation scheme
EP1646715B1 (en) 2003-07-22 2010-05-12 Vivalis Production of poxviruses with adherent or non adherent avian cell lines
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
WO2012063048A1 (en) * 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
US20130102031A1 (en) * 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
JP6262768B2 (ja) 2013-01-03 2018-01-17 セルトリオン， インク． 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物
AU2016243052C1 (en) * 2015-04-03 2022-11-24 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of B-cells
EP3313871A1 (en) 2015-06-26 2018-05-02 Institute for Research in Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
AU2016317936A1 (en) * 2015-09-04 2018-03-08 Tocagen Inc. Recombinant vectors comprising 2A peptide
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION

Similar Documents

Publication Publication Date Title
Xu et al. An engineered IL15 cytokine mutein fused to an anti-PD1 improves intratumoral T-cell function and antitumor immunity
JP2021525517A5 (https=)
JP7341900B2 (ja) 免疫療法のためのｃｄ１９組成物及び方法
Brog et al. Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors
JP2023080187A (ja) 増強されたキメラ抗原受容体およびその使用
Mac Donald et al. KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors
US20210260130A1 (en) Compositions and methods for inhibition of lineage specific antigens
EP4251741A1 (en) Gene-edited natural killer cells
Hare et al. An essential role for the IL-7 receptor during intrathymic expansion of the positively selected neonatal T cell repertoire
IL258491B2 (en) Preparations and methods for inhibiting antigens of a particular lineage
Maia et al. Genetic manipulation approaches to enhance the clinical application of NK cell-based immunotherapy
US20230014010A1 (en) Engineered cells with improved protection from natural killer cell killing
CN105384824A (zh) 嵌合抗原受体及其基因和重组表达载体、工程化her2靶向性的nkt细胞及其应用
US20250368954A1 (en) Myeloid lineages derived from pluripotent cells
AU2021285907A1 (en) Compositions and methods for inhibition of lineage specific antigens using crispr-based base editor systems
JP2023501580A (ja) キメラ抗原受容体を発現するｔ細胞を作製するための製造プロセス
Hudecek et al. Minicircle-based engineering of chimeric antigen receptor (CAR) T cells
Ma et al. Building a novel TRUCK by harnessing the endogenous IFN-gamma promoter for cytokine expression
Kasuya et al. High CD62L expression predicts the generation of chimeric antigen receptor T cells with potent effector functions
Chen et al. Rational protein design yields a CD20 CAR with superior antitumor efficacy compared with CD19 CAR
Arroyo-Olarte et al. Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer: R. Arroyo-Olarte et al.
CN105384822A (zh) 嵌合抗原受体及其基因和重组表达载体、工程化cd138靶向性的nkt细胞及其应用
JPWO2019229193A5 (https=)
CN101988049B (zh) 共表达小鼠膜型白细胞介素15和Rae-1ε的转基因细胞及其制备方法
BE1031219A1 (fr) Composition, cellules immunitaires la comprenant et utilisation de ces dernières